fibrobiologics.com (FBLG): Net earnings per share (EPS TTM)

Public company logo of FibroBiologics Corp (FBLG)

Is it worth investing in FibroBiologics, Inc. (FBLG), which has developed a unique system for combating multiple sclerosis and disc degeneration? The rolling 12-month net income per share provides the answer, and its current level is -5.62. FibroBiologics, Inc. (FBLG) is patenting tissue regeneration methods, offering affordable stem cell alternatives for cancer therapy. However, financial stability is currently based exclusively on venture capital and equity offerings.

FBLG (FibroBiologics Corp) Net earnings per share for the last four quarters history from 02/21/2024 to 11/15/2026

Analytical breakdowns for FibroBiologics, Inc. (FBLG)

- current quotes and average value forecast:
Price Chart FibroBiologics Inc.|FBLG - Analyst Median Target
- stock exchange capitalization data:
Market Capitalization FibroBiologics Inc.|FBLG - Full Business Value
- business book valuation details:
Book Value per Share FibroBiologics|FBLG - Book Valuation of Business|Market Capitalization to Book Value Ratio fibrobiologics.com|FBLG - Aggregate Company Assets
- debt and solvency information:
Debt to Equity FibroBiologics, Inc.|FBLG - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity FibroBiologics Corp|FBLG - Company Cumulative Debt|Debts to Book Capitalization FibroBiologics Corp|FBLG - Company Long-Term Debt|Company Short-Term Debts FibroBiologics|Quick Liquidity fibrobiologics.com
- net income and valuation multiples indicators:
FBLG - Company Net Income|Expected Profit FibroBiologics, Inc.|FBLG - Price to Earnings Ratio|Future Price to Earnings FibroBiologics Corp|FBLG - Price to Earnings Adjusted for Growth Rate|EV/EBITDA Multiple FibroBiologics Corp|FBLG - Operating profit before depreciation charges|Net earnings per share (EPS TTM) FibroBiologics|FBLG - Net earnings per share for the last four quarters|Quarterly EPS earnings growth fibrobiologics.com|FBLG - Net earnings per share growth this year|Net earnings per share growth forecast for next year FibroBiologics, Inc.
- total revenue and sales volume data:
FBLG - Company Gross Revenue|Company Future Sales Volume FibroBiologics|FBLG - Market Capitalization-to-Revenue Ratio|Forward P/S Multiple FibroBiologics|FBLG - Annual Revenue Growth (Last Twelve Months)
Basic company analysis:FibroBiologics Inc. (FBLG)
Mass-produced product of FibroBiologics Corp

FibroBiologics, Inc. (FBLG) is developing a unique fibroblast-based tissue regeneration technology protected by an extensive patent portfolio. The monetization of these innovations directly impacts the calculation of net income distributable to all shareholders. This indicator measures the business's actual ability to generate equity income, stripped of one-time factors. Analyzing the trend of the rolling 12-month earnings per share allows for an assessment of the operating model's sustainability. The stability of this line confirms the company's fundamental strength.

Competitor analysis for FibroBiologics, Inc.

MESO - Earnings per share for the last twelve months|Net earnings per share for the last four quarters Lineage Cell Therapeutics Inc LCTX|Surrozen Inc. (SRZN) - Earnings per share for the last twelve months|Net earnings per share for the last 12 months Cryo-Cell International Inc|Earnings per share for the last twelve months Longeveron Inc|biorestorative.com (BRTX) - Net earnings per share for the last four quarters|Net earnings per share (EPS TTM) CELZ